December 21, 2011
Salix released successful phase 3 clinical trial results for the oral version of Relistor and now plans to submit a new drug application for the compound in the middle of 2012.
November 15, 2011
Salix is preparing for new set of Xifaxan phase 3 clinical trials studying the irritable bowel syndrome indication, which puts approval about two years away. But first the company will meet with an FDA advisory panel on Wednesday, eight months after receiving the complete response letter from the agency declining approval on Xifaxan as a new IBS treatment.
Updated November 15, 2011
Triangle-based Salix wants to expand use of its bowel drug but the FDA raised questions that concern an analyst who follows the company.
November 11, 2011
"Napo believes Salix has materially breached the collaboration agreement by unnecessarily stalling the advancement of this compound," Napo Pharmaceuticals says. "Most notably, Salix has failed to file an NDA one year after a highly successful phase 3 clinical trial or to prepare for commercial manufacture of the drug -- critical tasks that were fundamental to its responsibilities."
November 9, 2011
"The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix's base business and provides immediate added revenue," says Salix CEO Carolyn Logan.
August 31, 2011
Salix and drug partner Progenics Pharmaceuticals want to expand Relistor's use to treat opioid-induded constipation in patients taking the drugs for non-cancer pain.
August 9, 2011
Data from proposed irritable bowel syndrome drug Xifaxan faces further review, Salix says. The FDA rejected Xifaxan as IBS tgreatment in March.
May 9, 2011
The Raleigh-based company says that the suit's charges "are without merit."
April 20, 2011
The Raleigh-based company expects Xifaxan sales to top $300 million this year.
March 1, 2011
The Raleigh-based pharmaceutical firm, whose stock was rocked last week by at FDA delay, reports sharp increase in profits and revenues from fourth quarter a year ago.
Updated February 25, 2011
The Raleigh-based pharmaceutical firm says the FDA wants more information about possible expanded use of a drug to treat non-constipation irritable bowel syndrome.
February 7, 2011
The Raleigh-based pharmaceutical firm signs a deal with N.Y.-based Progenics for the drug Relistor. Clinical trials are underway on an oral version of the drug, which now is administered by injection.
Updated January 6, 2011
Report in New England Journal of Medicine says antibiotic Xifaxan shows promise.
Updated November 9, 2010
The Triangle-based pharmaceutical firm beats Wall Street expectations with a 5-cent per share profit. Its revenues surge 23 percent from a year ago.
November 5, 2010
October 20, 2010
Salix believes Lumacan will boost effectiveness of colonoscopies and produce annual sales topping $500 million. The Raleigh-based pharmaceutical firm pays $4 million up front for rights to the drug from Norway-based Photocure.
Updated October 4, 2010
Review date pushed out three months for added use of drug-maker's Xifaxan tablets, but the company sees no problem.
Updated August 10, 2010
Raleigh-based company also reports huge surge in revenues for second quarter.
June 8, 2010
May 28, 2010
The Raleigh-based firm said Thursday it would sell $200 million in debt. Proceeds will be used in part for product commercialization, research and development and clinical trials, Salix says.